Novartis, Cota Healthcare re-up on breast cancer

The Cota Nodal Address technology stratifies patients using their personal and clinical data. (Cota Healthcare)

Novartis and precision medicine player Cota Healthcare have inked a multiyear partnership to improve clinical outcomes and reduce costs for breast cancer patients.

Novartis will tap Cota Healthcare’s web-based analysis and visualization tools, as well as its medical, data science and technology experts, to ramp up its development of new breast cancer treatments and to identify the patients who would benefit most, Cota said in a statement.

Cota’s platform is based on its Cota Nodal Address technology, which uses personal and clinical information to classify patients into different groups. Patients in the same group, or CNA, may be considered medically identical, and so, should have similar treatments and similar outcomes, Cota said.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

RELATED: Celgene, Novartis back precision medicine analytics startup after recent board addition from CMS

The new deal builds on a previous collaboration the pair entered in January last year, with the same objective.

"Data and insight that comes directly from patient records—real-world evidence—is transforming how pharmaceutical and life science companies develop more precise, targeted therapies," said Cota CEO John Hervey, in the statement. "Novartis has been an incredible collaborator over the last several years in adopting Cota's real-world evidence solutions to advance our shared goal of quantifiably improving and extending patient lives."

Suggested Articles

The FDA broadened its approval of Medtronic’s transcatheter aortic valve replacement to include patients at a low risk of surgical complications.

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.